Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2011-04-26 Board/Management Inform…
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which relates to the departure or election of directors or officers and compensation arrangements. Specifically, it discusses an amendment to the company's incentive plan increasing authorized shares, subject to stockholder approval. There is no detailed financial data or full report content, but rather an announcement of a board decision and related corporate governance matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes or arrangements involving the company's board or senior management. The document length is short (2632 characters), consistent with a typical 8-K announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2011-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2011-04-22 English
FORM 4 SUBMISSION
Director's Dealing
2011-04-22 English
FORM 4/A SUBMISSION
Director's Dealing
2011-04-22 English
FORM 4 SUBMISSION
Director's Dealing
2011-04-22 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is under Item 3.01, which is a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The document discusses Nasdaq notifying the company about non-compliance with listing rules and subsequent resolution. The document length is 3100 characters, which is relatively short and is an announcement rather than a full report. The content clearly matches the definition of a Delisting Announcement (DLST) as it concerns listing compliance and Nasdaq rules. Therefore, the appropriate classification is DLST with high confidence.
2011-04-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.